Search

Your search keyword '"Stiefel, Olga"' showing total 13 results
Start Over Author "Stiefel, Olga"
13 results on '"Stiefel, Olga"'

3. Outcomes of pirtobrutinib for relapsed/refractory mantle cell lymphoma in compassionate use program in Europe

Author

Aydilek, Enver, primary, Wulf, Gerald, additional, Schwarz, Friedrich, additional, Bacher, Ulrike, additional, Rummel, Mathias, additional, Stiefel, Olga, additional, Kerkhoff, Andrea, additional, Maulhardt, Markus, additional, Melchardt, Thomas, additional, Pabst, Thomas, additional, Lenz, Georg, additional, and Shumilov, Evgenii, additional

Published
2024
Full Text
View/download PDF

4. Allogeneic Stem Cell Transplantation in Multiple Myeloma: Risk Factors and Outcomes in the Era of New Therapeutic Options—A Single-Center Experience

Author

Strassl, Irene, primary, Nikoloudis, Alexander, additional, Machherndl-Spandl, Sigrid, additional, Buxhofer-Ausch, Veronika, additional, Binder, Michaela, additional, Wipplinger, Dagmar, additional, Stiefel, Olga, additional, Kaynak, Emine, additional, Milanov, Robert, additional, Aichinger, Christoph, additional, Nocker, Stefanie, additional, Bauer, Thomas, additional, Kreissl, Stefanie, additional, Girschikofsky, Michael, additional, Petzer, Andreas, additional, Weltermann, Ansgar, additional, and Clausen, Johannes, additional

Published
2023
Full Text
View/download PDF

5. Successful SARS-CoV-2 mRNA Vaccination Program in Allogeneic Hematopoietic Stem Cell Transplant Recipients—A Retrospective Single-Center Analysis

Author

Nikoloudis, Alexander, primary, Neumann, Ines Julia, additional, Buxhofer-Ausch, Veronika, additional, Machherndl-Spandl, Sigrid, additional, Binder, Michaela, additional, Kaynak, Emine, additional, Milanov, Robert, additional, Nocker, Stefanie, additional, Stiefel, Olga, additional, Strassl, Irene, additional, Wipplinger, Dagmar, additional, Moyses, Margarete, additional, Kerschner, Heidrun, additional, Apfalter, Petra, additional, Girschikofsky, Michael, additional, Petzer, Andreas, additional, Weltermann, Ansgar, additional, and Clausen, Johannes, additional

Published
2023
Full Text
View/download PDF

6. PB2134: BCMA-TARGETED THERAPIES IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AFTER ALLOGENEIC STEM CELL TRANSPLANTATION – A SINGLE CENTER EXPERIENCE

Author

Strassl, Irene, primary, Machherndl-Spandl, Sigrid, additional, Buxhofer-Ausch, Veronika, additional, Binder, Michaela, additional, Stiefel, Olga, additional, Milanov, Robert, additional, Kaynak, Emine, additional, Girschikofsky, Michael, additional, Petzer, Andreas, additional, and Clausen, Johannes, additional

Published
2023
Full Text
View/download PDF

7. PB2186: MOLECULAR RESPONSE TO INTERFERON IN PREFIBROTIC PRIMARY MYELOFIBROSIS- RETROSPECTIVE SINGLE CENTER STUDY

Author

Kaynak, Emine, primary, Sygulla, Veronika, additional, Zach, Otto, additional, Webersinke, Gerald, additional, Foedermayr-Mayrleitner, Mathilde, additional, Gruber, Christine, additional, Schimetta, Wolfgang, additional, Clausen, Johannes, additional, Strassl, Irene, additional, Stiefel, Olga, additional, Machherndl-Spandl, Sigrid, additional, Moyses, Margarete, additional, Girschikofsky, Michael, additional, Petzer, Andreas, additional, and Buxhofer-Ausch, Veronika, additional

Published
2023
Full Text
View/download PDF

8. Relapse Protection Following Early Cytomegalovirus Reactivation after Hematopoietic Stem Cell Transplantation Is Limited to HLA-C Killer Cell Immunoglobulin-Like Receptor Ligand Homozygous Recipients

Author

Nikoloudis, Alexander, Wagner, Helga, Machherndl-Spandl, Sigrid, Buxhofer-Ausch, Veronika, Strassl, Irene, Stiefel, Olga, Wipplinger, Dagmar, Milanov, Robert, Kaynak, Emine, Hasengruber, Petra, Binder, Michaela, Weltermann, Ansgar, Petzer, Andreas, Wolf, Dominik, Nachbaur, David, and Clausen, Johannes

Published
2021
Full Text
View/download PDF

9. Comparison of Benefits and Risks Associated with Anti-T-Lymphocyte Globulin (ATLG) Serotherapy in Methotrexate (MTX)- versus Mycophenolate Mofetil (MMF)-Based Hematopoietic Stem Cell Transplantation

Author

Nikoloudis, Alexander, primary, Strassl, Irene, additional, Binder, Michaela, additional, Stiefel, Olga, additional, Wipplinger, Dagmar, additional, Milanov, Robert, additional, Aichinger, Christoph, additional, Kaynak, Emine, additional, Machherndl-Spandl, Sigrid, additional, Buxhofer-Ausch, Veronika, additional, Böhm, Alexandra, additional, Petzer, Andreas, additional, Weltermann, Ansgar, additional, Wolf, Dominik, additional, Nachbaur, David, additional, and Clausen, Johannes, additional

Published
2023
Full Text
View/download PDF

10. Impact of the Recipient's Pre-Treatment Blood Lymphocyte Count on Intended and Unintended Effects of Anti-T-Lymphocyte Globulin in Allogeneic Hematopoietic Stem Cell Transplantation.

Author

Nikoloudis, Alexander, Buxhofer-Ausch, Veronika, Aichinger, Christoph, Binder, Michaela, Hasengruber, Petra, Kaynak, Emine, Wipplinger, Dagmar, Milanov, Robert, Strassl, Irene, Stiefel, Olga, Machherndl-Spandl, Sigrid, Petzer, Andreas, Weltermann, Ansgar, and Clausen, Johannes

Subjects
HEMATOPOIETIC stem cell transplantation, LYMPHOCYTE count, GLOBULINS, GRAFT versus host disease
Abstract

Background: In allogeneic hematopoietic stem cell transplantation (HSCT), Anti-T-Lymphocyte Globulin (ATLG) may be used for the prevention of severe graft-versus-host disease (GVHD). ATLG targets both the recipient's lymphocytes and those transferred with the graft. Assuming an inverse relation between the recipient's absolute lymphocyte count (ALC) and exposure of remaining ATLG to the graft, we aim to evaluate the impact of the recipient's ALC before the first ATLG administration on the benefits (prevention of GVHD and GVHD-associated mortality) and potential risks (increased relapse incidence) associated with ATLG. Methods: In recipients of HLA-matched, ATLG-based HSCT (n = 311), we assessed the incidence of acute GVHD, GVHD-related mortality and relapse, as well as other transplant-related outcomes, in relation to the respective ALC (divided into tertiles) before ATLG. Results: The top-tertile ALC group had a significantly increased risk of aGVHD (subhazard ratio (sHR) 1.81; [CI 95%; 1.14–2.88]; p = 0.01) and aGVHD-associated mortality (sHR 1.81; [CI 95%; 1.03–3.19]; p = 0.04). At the highest ATLG dose level (≥45 mg/kg), recipients with lowest-tertile ALC had a trend towards increased relapse incidence (sHR 4.19; [CI 95%; 0.99–17.7]; p = 0.05, n = 32). Conclusions: ATLG dosing based on the recipient's ALC may be required for an optimal balance between GVHD suppression and relapse prevention. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

12. HLA-C KIR-Ligands Determine the Impact of Anti-Thymocyte Globulin (ATG) on Graft versus Host and Graft versus Leukemia Effects Following Hematopoietic Stem Cell Transplantation

Author

Clausen, Johannes, primary, Böhm, Alexandra, additional, Straßl, Irene, additional, Stiefel, Olga, additional, Buxhofer-Ausch, Veronika, additional, Machherndl-Spandl, Sigrid, additional, König, Josef, additional, Schmidt, Stefan, additional, Steitzer, Hansjörg, additional, Danzer, Martin, additional, Kasparu, Hedwig, additional, Weltermann, Ansgar, additional, and Nachbaur, David, additional

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results